Oncology FISH Analysis - MDS FISH Panel

Clinical Use

Use

Oncology FISH Analysis - MDS is a Fluorescence In Situ Hybridization (FISH) test designed to detect chromosomal abnormalities linked to myelodysplastic syndrome (MDS), offering insights into both diagnosis and prognosis. The assay identifies key cytogenetic markers, such as monosomy 5, monosomy 7, and others, which are important in evaluating the disease progression. Given that MDS can lead to acute myeloid leukemia (AML), early detection of these abnormalities can significantly impact patient outcomes. All results should be interpreted in conjunction with comprehensive clinical data, acknowledging the risks of infection, anemia, and bleeding.

Special Instructions

This test should be ordered when a patient exhibits symptoms indicative of Myelodysplastic Syndrome. Sending specimens promptly is critical, and they should arrive at the laboratory within 48 hours of collection. It’s essential to instruct couriers accordingly and to avoid storage conditions that may compromise specimen integrity such as freezing. Ensure that the ordering physician has comprehensive clinical data for the most effective interpretation of results, as FISH analysis is not standalone for diagnosing MDS.

Limitations

This FISH assay has notable limitations as it is designed only to identify gain or loss involving specific loci and does not detail translocations or identify partners for the KMT2A locus. Specimens must adhere strictly to collection protocols to ensure the accuracy of results and avoid misinterpretation. Results should be regarded in the broader clinical context, not as standalone diagnostic tools.

Test Details